CONTENT VALIDATION AND DISCLOSURES
Research To Practice is committed to providing its participants with high-quality, unbiased and state-of-
the-art education. We assess potential conflicts of interest with faculty, planners and managers of
CME activities. Real or apparent conflicts of interest are identified and resolved by a peer review content
validation process. The content of each activity is reviewed by both a member of the scientific staff
and an external independent reviewer for fair balance, scientific objectivity of studies referenced and
patient care recommendations.
The scientific staff and consultants for Research To Practice are involved in the development
and review of content for educational activities and report the following real or apparent
conflicts of interest, either current or within the past 12 months, for themselves (or their
spouses/partners) that have been resolved through a peer review process: Clayton Campbell,
Karen Green, MD, Anne Jacobson, MPH, Richard Kaderman, PhD, Neil Love, MD, Douglas Paley,
Margaret Peng, Lilliam Sklaver Poltorack, PharmD, Chris Thomson, MD, MS, Erin Wall and Kathryn Ault
Ziel, PhD — no real or apparent conflicts of interest to report; Aviva Asnis-Alibozek, PA-C, MPAS —
salary: AstraZeneca Pharmaceuticals LP; shareholder of AstraZeneca Pharmaceuticals LP; Marie Bialek,
PharmD — Freelance/Contract Medical Writer: McNeil Consumer & Specialty Pharmaceuticals; Sally
Bogert, RNC, WHCNP — shareholder of Amgen Inc and Genentech BioOncology. Research To Practice
receives education grants from Abraxis BioScience, Amgen Inc, AstraZeneca Pharmaceuticals LP,
Bayer Pharmaceuticals Corporation/Onyx Pharmaceuticals Inc, Biogen Idec, Genentech BioOncology/
OSI Pharmaceuticals Inc, Genomic Health Inc, GPC Biotech, Roche Laboratories Inc and Sanofi-
Aventis, who have no influence on the content development of our educational activities.
In addition, the following faculty (and their spouses/partners) have reported real or apparent conflicts
of interest that have been resolved through a peer review process:
Dr Hurwitz — Consulting Fees and Contracted Research: Bristol-Myers Squibb Company, Genentech
BioOncology, Roche Laboratories Inc; Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers
Squibb Company, Genentech BioOncology, GlaxoSmithKline, Pfizer Inc, Roche Laboratories Inc, Sanofi-Aventis,
Sunesis Pharmaceuticals Inc; Fees for Non-CME Services Received Directly from Commercial Interest or Their
Agents: Genentech BioOncology. Dr Tepper — No financial interests or affiliations to disclose. Dr Goldberg —
Consulting Fees: Amgen Inc, AstraZeneca Pharmaceuticals LP, Boehringer Ingelheim GmbH, Bristol-Myers Squibb
Company, Genentech BioOncology, ImClone Systems, Pfizer Inc, Sanofi-Aventis. Dr Eng — Contracted Research: AstraZeneca Pharmaceuticals LP, Bristol-Myers Squibb Company, Genentech BioOncology, Pfizer Inc, Roche
Laboratories Inc, Sanofi-Aventis.
This educational activity contains discussion of published and/or investigational uses of agents that are
not indicated by the Food and Drug Administration. Research To Practice does not recommend the use
of any agent outside of the labeled indications. Please refer to the official prescribing information for each
product for discussion of approved indications, contraindications and warnings. The opinions expressed
are those of the presenters and are not to be construed as those of the publisher or grantors.
